博瑞医药(688166) - 2023 Q1 - 季度财报

Financial Performance - The company reported a revenue of CNY 304,937,396.25 for Q1 2023, representing a year-on-year increase of 22.77%[4] - Net profit attributable to shareholders was CNY 70,769,470.45, reflecting a growth of 16.48% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 69,711,194.90, up by 15.58% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.17, an increase of 13.33% from the previous year[4] - In Q1 2023, the company achieved product sales revenue of CNY 267.94 million, a year-on-year increase of 19.90%[37] - The revenue from raw material products was CNY 221.18 million, up 6.50% year-on-year[37] - The revenue from formulation products reached CNY 46.75 million, a significant increase of 196.10% year-on-year, accounting for 17.45% of total product sales revenue, up 10.38 percentage points from the previous year[37] - Technology revenue amounted to CNY 24.64 million, reflecting a growth of 38.35% compared to the same period last year[37] - Equity income reached CNY 12.37 million, representing a substantial increase of 75.69% year-on-year[37] - Operating profit for Q1 2023 was RMB 75,605,620.79, an increase from RMB 65,287,387.64 in Q1 2022[45] Research and Development - Total R&D investment amounted to CNY 48,657,672.09, which is 15.96% of the revenue, a decrease of 1.25 percentage points compared to last year[4] - The company submitted 27 domestic patent applications and 6 international patent applications in Q1 2023, with a total of 397 patent applications filed to date[19] - The company reported a total of 205 valid patents, including 197 invention patents, as of March 31, 2023[19] - The company’s research and development center project is in the equipment installation and debugging phase, with significant advancements in the construction of the production base[21] Assets and Liabilities - The company's total assets at the end of Q1 2023 were CNY 4,777,033,986.25, a 2.48% increase from the end of the previous year[5] - In Q1 2023, the company achieved a total asset of approximately CNY 4.78 billion, an increase from CNY 4.66 billion in the previous quarter, reflecting a growth of about 2.5%[22] - The company’s total liabilities increased to approximately CNY 1.86 billion from CNY 1.83 billion, indicating a growth of about 1.6%[24] - The total liabilities decreased slightly to CNY 2,408.38 million from CNY 2,419.59 million year-on-year[26] - The total equity increased to CNY 2,368.65 million from CNY 2,241.69 million year-on-year[27] Cash Flow and Investments - The company's net cash flow from operating activities was CNY 25.06 million, compared to a negative cash flow of CNY 29.65 million in the same period last year[32] - The company reported a net increase in cash and cash equivalents of CNY -162.47 million, compared to CNY -8.75 million in the same period last year[35] - Cash and cash equivalents decreased to approximately CNY 1.02 billion from CNY 1.18 billion, representing a decline of about 13.7%[22] - The company’s long-term equity investments decreased slightly to approximately CNY 33.92 million from CNY 35.37 million, a decline of about 4.1%[24] - The company’s short-term borrowings increased to approximately CNY 164.35 million from CNY 124.38 million, reflecting a rise of about 32.2%[24] Infrastructure Development - The company completed 90% of the curtain wall construction for the workshop and 95% for the headquarters building, indicating significant progress in infrastructure development[21] - The company is preparing for trial production at several new facilities, including the Taixing raw material and formulation production base[10] Market Strategy - The company plans to continue expanding its market presence and investing in new product development[44] - The company is not applying new accounting standards for the year 2023[48]